Pharmaceutical

Cardurion closes $260m in Series B to develop cardiovascular pipeline

The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.

Jul 18, 2024 - 04:00
Cardurion closes $260m in Series B to develop cardiovascular pipeline
The funds will finance late-stage trials of CRD-750, a PDE9 inhibitor for heart failure, and CRD-4730, a CaMKII inhibitor.
Read the original article

Tags:

Previous Article

CatalYm secures $150m to advance GDF-15-targeting immune modulator   

Next Article

The US Biosecure Act threatens to destabilise the pharmaceutical industry 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: 1 in 5 primary endpoints changed in late-stage trials of cancer drugs already underway, study finds

STAT+: 1 in 5 primary endpoints changed in late-stage t...

May 19, 2023

(Glucagon + insulin human) by Abvance Therapeutics for ...

Jul 1, 2023

STAT+: Gene therapy makers wonder if they can make a profit in Europe. Patients fear being left behind — again

STAT+: Gene therapy makers wonder if they can make a pr...

Oct 4, 2023